Table 1.
Patient and transplant characteristics.
| Patients (n=69) | |
|---|---|
| Sex (female, %) | 61 (88) |
| Age (median, IQR) | 55 (46-61) |
| Diagnosis (n, %): • AML/MDS • ALL • Non-Hodgkin lymphoma • Hodgkin lymphoma • Plasma cell leukemia • Myelofibrosis • Severe aplastic anemia |
49 (71.5) 8 (12) 5 (7) 4 (6) 1 (1.5) 1 (1.5) 1 (1.5) |
| Disease risk index (n, %) • Low • Intermediate • High/Very High • Not-applicable |
4 (6) 35 (50.5) 29 (42) 1 (1.5) |
| HCT-CI score (n, %) • 0-2 • ≥3 |
36 (52) 33 (48) |
| Sensitization events (n, %) • Polytransfusion only • 1-2 pregnancies + polytransfusion • 3-4 pregnancies + polytransfusion |
14 (20) 39 (57) 16 (23) |
| Prior HSCT (n, %) • Autologous • Allogeneic • MSD • MUD • Haploidentical |
4 (6) 4 (6) 1 2 1 |
| Donor (n, %) • Sibling • Child • Parent • 2nd degree relative |
27 (40) 37 (53) 3 (4) 2 (3) |
| Stem cell source PB (n, %) | 62 (90) |
| Graft counts • CD34+ cells (x106/kg) (median, range) (PB) • TNC (x108/kg) (median, range) (BM) |
6.6 (2.5─15) 2.7 (1.5─6.7) |
| Conditioning regimen intensity (n, %) • Myeloablative • Reduced intensity • Sequential regimen |
32 (46) 35 (51) 2 (3) |
| CMV serostatus (n, %) • Donor and recipient positive • Donor and recipient negative • Donor negative, recipient positive • Donor positive, recipient negative |
49 (71) 4 (6) 15 (22) 1 (1) |
| ABO incompatibility (n, %) • None • Major • Minor • Bidirectional |
53 (77) 6 (9) 9 (13) 1 (1) |
ALL, acute lymphoid leukemia; AML, acute myeloid leukemia; BM, bone marrow; CMV, cytomegalovirus; HSCT, hematopoietic stem cell transplant; HCT-CI, Hematopoietic Cell Transplantation-Comorbidity Index; IQR, interquartile range; MDS, myelodysplastic syndrome; MSD, matched sibling donor; MUD, matched unrelated donor; PB, peripheral blood; TNC, total nucleated cell count.
One patient with DSAs underwent two transplants; the second procedure is not described.